News | Treatment Planning | September 23, 2019

First Patients Treated With Machine Learning-generated Plans from RayStation 8B

Patients treated at Princess Margaret Cancer Centre in Toronto, Canada, as part of comprehensive evaluation study

First Patients Treated With Machine Learning-generated Plans from RayStation 8B

September 23, 2019 — The first-ever patient radiation therapy treatments generated with machine learning in the RayStation treatment planning system (TPS) have been conducted. Patients with localized prostate cancer are being treated with the technology at the Princess Margaret Cancer Centre in Toronto, Canada, as part of a comprehensive evaluation study.

RaySearch released the machine learning features in RayStation 8B in late December 2018. This technology has been developed by RaySearch’s in-house machine learning department in collaboration with researchers at the Princess Margaret Cancer Centre and Techna Institute, crystalizing years of cutting-edge research led by medical physicist Tom Purdie, Ph.D., and computer scientist Chris McIntosh, Ph.D. The features represent the first applications of machine learning in a TPS on the radiation oncology market, according to RaySearch, producing high-quality radiation treatment plans in only minutes, without the need for any user intervention.

Since May 2019, every patient with localized prostate cancer treated at the Princess Margaret has been part of a prospective initiative under the direction of radiation oncologist Alejandro Berlin, M.D. The initiative was launched after observing excellent clinical results in a retrospective evaluation study conducted during 2018, in which machine learning plans were preferred or deemed equivalent to previous manual plans based on three blinded expert reviewers in 94 percent of cases.

The ongoing phase of this study presents physicians with two blinded treatment plans: a manually generated plan and a machine learning plan. The selected plan undergoes standard peer-review and quality assurance, and then patients proceed to treatment delivery with the preferred plan.

This worldwide endeavor will provide unique data to quantify the performance and preferability of machine learning plans in the real-world environment.

Berlin said, “It has been really exciting for the team to help materialize this machine learning advancement in the radiation oncology field, including deployment into the clinical realm. Our positive results to date validate our observations about the robustness of this planning solution”.

For more information: www.raysearchlabs.com

Related Content

Sponsored Content | Videos | Enterprise Imaging | February 19, 2020
Bill Lacy, vice president, Medical Informatics at FUJIFILM Medic...
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment
The Caption Guidance software uses artificial intelligence to guide users to get optimal cardiac ultrasound images in a point of care ultrasound (POCUS) setting.

The Caption Guidance software uses artificial intelligence to guide users to get optimal cardiac ultrasound images in a point of care ultrasound (POCUS) setting.

News | Artificial Intelligence | February 13, 2020
February 13, 2020 — The U.S.
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
PaxeraHealth enterprise imaging, PACS, VNA solutions
News | Enterprise Imaging | February 11, 2020
February 11, 2020 — Enterprise Imaging developer PaxeraHealth
Mammograms of a 49-year-old woman with invasive lobular carcinoma on the right-side breast

Mammograms of a 49-year-old woman with invasive lobular carcinoma on the right-side breast. A small mass with micro-calcifications on the right-side breast was detected correctly by AI with an abnormality score of 96%. This case was recalled by 7 out of 14 radiologists (4 breast radiologists and 3 general radiologists) initially (without AI) and all 14 radiologists recalled this case correctly with the assistance of AI.

News | Artificial Intelligence | February 11, 2020
February 11, 2020 — A new study, published in...
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
SIR President Laura Findeiss, M.D., FSIR

SIR President Laura Findeiss, M.D., FSIR

News | Interventional Radiology | February 09, 2020
February 9, 2020 — For some patients, kidney cancer can be effectively treated without surgery, according to the...